Industry News
FDA approves GroPep-based biopharma product
A biopharmaceutical product that uses GroPep's (ASX:GRO) cell culture products in its manufacturing process has received US Food and Drug Administration (FDA) regulatory approval. [ + ]
Domantis find expected to benefit Abbott
UK antibody therapeutics developer Domantis has pulled a double-headed rabbit out of the hat for its client, the big European pharma Abbott Laboratories. [ + ]
Genesis Biomed boosts advisory board, starts CEO hunt
Sydney-based Genesis Biomedical (ASX:GBL) is moving to raise its profile in the Australian biomedical marketplace, after appointing two more senior researchers to its new strategic advisory committee. [ + ]
XRT signs electron microscope deal with Gatan
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal with Californian-based electron microscope accessory and software manufacturer Gatan to develop and distribute an x-ray microscope product for use with electron microscopes. [ + ]
New members named to biotech advisory council
Four new members have been appointed to the Australian Biotechnology Advisory Council (ABAC) -- the independent board of industry experts advising the government on biotech issues. [ + ]
We're out of start-up phase: Cryptome
Eighteen months after its AUD$6.6 million IPO in November 2003, Melbourne-based Cryptome Pharmaceuticals (ASX:CRP) has achieved all of the objectives listed in its IPO prospectus and claims that it is no longer in the start-up phase. [ + ]
Biosignal nets global contact lens deal
Sydney's Biosignal (ASX:BOS) and its partner, the Institute for Eye Research (IER), have closed a deal with an international contact lens manufacturer to develop anti-bacterial daily disposable and other frequent replacement contact lenses for eventual sale to the US and European markets. [ + ]
CSIRO robots team up with MIT
Australian robotics research has received some fresh input as a new partnership between the CSIRO and the MIT computer science and artificial intelligence laboratory in USA has been formed.
[ + ]Alchemia heartened by thumbs-up for Glaxo drug
Shares in Brisbane biopharma Alchemia (ASX:ACL) rose 7 per cent today on news that the US Food and Drug Administration has approved GlaxoSmithKline's anti-thrombotic drug Arixtra in surgical patients at high risk of life-threatening venous blood clots. [ + ]
AustCancer changes name, sets course for US
Oncology drug developer Australian Cancer Technology (ASX:ACU) has changed its name to Avantogen, and flagged its intention to relocate its headquarters to San Diego, on the US west coast, within a few years. [ + ]
Tissue Therapies patent accepted in Australia
The core patent for Tissue Therapies' (ASX:TIS) VitroGro growth factor complex, used to accelerate wound healing, has been accepted in Australia. [ + ]
Aust biotech posts three-year performance low: PwC
A new report on ASX-listed life sciences companies by PricewaterhouseCoopers shows that the sector has posted its worst quarterly performance in three years. [ + ]
Biotech pioneer BresaGen resurrected as service company
The dark clouds over venerable Adelaide biopharma BresaGen (ASX:BGN) have parted, revealing a little blue sky. But the resurrected company's business plan is focused on terra firma -- it is going back to its roots as a service company. [ + ]
Heraeus Noblelight acquires Spectral
Heraeus Noblelight has acquired the Spectral Technologies division of US company IST Corporation. IST Spectral Technologies is a manufacturer of light sources for analytical instrumentation.
[ + ]Fine chemical finesse
Sigma-Aldrich has a new identity for its fine chemicals business, SAFC. SAFC will have over 650 of Sigma-Aldrich's 6000 employees dedicated to its success and will embrace the company's recent acquisitions, Ultrafine and Tetrionics.
[ + ]
